AGM / EGM Postponed to July 20, 2008
18 July 2008 - 1:10AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., July 17 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces that the
Annual General Meeting ("AGM") and Extraordinary General Meeting
("EGM") scheduled for today were adjourned and postponed until
Sunday, July 20, 2008 at 4:00pm and 4:30 pm Israel time,
respectively. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of diabetic neuropathic pain and
HCV. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain,
which is currently in a Phase 2b study. XTL has out-licensed its
novel pre-clinical HCV small molecule inhibitor program. XTL also
has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024
